Medicine
Bimzelx 320 mg/2 mL injection
Bimzelx 320 mg/2 mL injection is a prescription medicine containing Bimekizumab for subcutaneous use, marketed by UCB, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store cartons with BIMZELX refrigerated between 2°C to 8°C (36°F to 46°F). Do…
Key facts
- Active ingredient (INN)
- Bimekizumab
- Brand
- Bimzelx
- Strength
- 320 mg/2 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 1 syringe of 2 mL
- Marketing authorisation holder
- UCB
- Manufacturer
- UCB
- Origin register
- US FDA, United States
- Storage
- Store cartons with BIMZELX refrigerated between 2°C to 8°C (36°F to 46°F). Do not freeze. Once BIMZELX prefilled syringes or autoinjectors have been stored at room temperature, do not place back in refrigerator. When necessary, BIMZELX prefilled syringes or autoinjectors may be stored at room temperature up to 25°C (77°F) in the original carton for a single period of up to 30 days.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L04AC Immunosuppressive drug, subgroup L04AC
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 5 December 2024
- Identifiers
- DailyMed set ID 26b88358-871f-4c80-9d80-b2fb16477f81NDC 50474-783, 50474-782Application BLA761151
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Bimekizumab
Clinical summary
Bimekizumab is a prescription medicine indicated for the treatment of moderate to severe plaque psoriasis (PSO) in adults who are candidates for systemic therapy or phototherapy, among other approved uses. MedsAcross supplies Bimekizumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about BimekizumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Bimzelx prescribing information (UCB) · U.S. National Library of Medicine, DailyMed
- Bimzelx: European public assessment report (EPAR) · European Medicines Agency
Need Bimzelx 320 mg/2 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.